Table 1.

Recent successful targeted therapy in oncology

TargetPredictive markerTherapyTumor typeResponse rate (%)StudyFDA/EMA approved
C-kitC-kit mutationImatinibGIST54Demetri et al., 2002 (1)Yes
EGFREGFR mutationGefitinibNSCLC71Maemondo et al., 2010 (17)Yes (EMA)
ALKALK-EML translocationCrizotinibNSCLC57Kwak et al., 2010 (2)“Fast track” (FDA)
BRAFBRAF V600E mutationBRAF inhibitorMelanoma77Flaherty et al., 2010 (3)“Fast track” (FDA)
PARPGermline BRCA1/2 mutationOlaparibBreast, ovary41Tutt et al. and Audeh et al., 2010 (10, 11)Not requested

Abbreviations: EGFR, epidermal growth factor receptor; NSCLC, non–small cell lung cancer.